CYP19A1 and breast carcinoma: Pedersini et al. [15] found, for breast cancer patients treated with 18 months of aromatase inhibitors (AI), a significant increase in fat mass (+7.2%, p < 0.01) and visceral fat mass (+18.9%, p < 0.01).